Results 191 to 200 of about 252,165 (283)

Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis. [PDF]

Leukemia
Agathangelidis A, Iatrou A, Pechlivanis N, Karakatsoulis G, Zaragoza-Infante L, Galigalidou C, Maity PC, Ranghetti P, Almeida J, Fuentes-Herrero B, Navarro A, Alcoceba M, Rabbani L, Thorvaldsdottir B, Scarfò L, Orfao A, Psomopoulos F, Jumaa H, Rosenquist R, Chatzidimitriou A, Ghia P, Stamatopoulos K.   +21 more
europepmc   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 383-395, February 2026.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Immunoglobulin heavy-chain status and stromal interactions shape ferroptosis sensitivity in chronic lymphocytic leukemia. [PDF]

Signal Transduct Target Ther
Böttcher M, Reemts L, Hengeveld PJ, Böttcher-Loschinski R, Bhuria V, Lu J, Materna-Reichelt S, Das D, Stojanović Gužvić N, Bruns H, Huber W, Zenz T, Schanze D, Zenker M, Dietrich S, Langerak AW, Mougiakakos D.   +16 more
europepmc   +1 more source

The role and regulation of AKT in CD40-mediated survival and proliferation of CLL cells

, 2016
Elinor Chapman
openalex   +1 more source

Real‐world evidence of tirbanibulin in the treatment of actinic keratosis in Germany – prospective, multicenter, non‐interventional KLIR study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 2, Page 186-193, February 2026.
Summary Background Tirbanibulin is an approved topical treatment for actinic keratosis (AK). This non‐interventional study investigated effectiveness and safety of tirbanibulin for AK. Patients and Methods The prospective KLIR‐study was conducted at 58 German dermatology centers (02/2022–09/2023).
Markus V. Heppt, Ina Hadshiew, Afra Kempf, Antje Melzer, Carola Berking   +4 more
wiley   +1 more source

Clinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel. [PDF]

Front Med (Lausanne)
Alotaibi G, Aleem A, Absi A, Alaskar AS, Alfraih F, Alhejazi A, Almasari A, Alzahrani MF, Motabi I, El Fakih R.   +9 more
europepmc   +1 more source

Real‐World‐Daten zu Tirbanibulin bei aktinischer Keratose in Deutschland ‐ Prospektive multizentrische nichtinterventionelle KLIR‐Studie

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 2, Page 186-194, February 2026.
Zusammenfassung Hintergrund In dieser nichtinterventionellen Studie wurde die Wirksamkeit und Sicherheit von Tirbanibulin, einem zugelassenen topischen Medikament zur Behandlung aktinischer Keratosen (AK), untersucht. Patienten und Methodik Die prospektive nichtinterventionelle Studie wurde an 58 dermatologischen Kliniken und Praxen in Deutschland ...
Markus V. Heppt, Ina Hadshiew, Afra Kempf, Antje Melzer, Carola Berking   +4 more
wiley   +1 more source

Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B-cell-related epigenetic imprinting and genetic alterations. [PDF]

Hemasphere
Charalampopoulou S, Ramos-Campoy S, Duran-Ferrer M, Puiggros A, Kamaso J, Nguyen-Khac F, Rigolin GM, Cuneo A, Collado R, García-Serra R, Haferlach C, Ortega M, Abrisqueta P, Bosch F, Zenz T, Blanco ML, Salgado R, García-Malo MD, Gimeno E, Lopez-Guillermo A, Campo E, Etter L, Schoumans J, Espinet B, Martin-Subero JI.   +24 more
europepmc   +1 more source

CLL

Annals of Oncology, 2011
openaire   +2 more sources

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source